Ron DePinho, Professor of Department of Cancer Biology, Division of Discovery Science at MD Anderson Cancer Center, shared on LinkedIn:
“Cancer cells can escape treatment by changing their identity. A Nature study identifies an unexpected regulator of this process … the abundance of a specific transfer RNA.
tRNA1Arg(UCU) controls a translational program centered on SWI/SNF chromatin remodelers, helping maintain prostate cancer lineage identity. Manipulating its expression can restore sensitivity to androgen receptor–targeted therapies in experimental models.
In patient samples, this tRNA is reduced in neuroendocrine prostate cancer, and its loss is associated with accelerated metastasis and poor survival.
The work opens a new area of biology connecting codon biology, chromatin regulation, and therapeutic resistance, revealing how the machinery that translates genetic information can shape cancer-cell identity and treatment response. An interesting direction for understanding and potentially overcoming lineage plasticity.”
Title: tRNA dosage regulates lineage dependency and resistance in prostate cancer
Authors: Yeon Soo Kim, Sonali Arora, Dave Young, Ava Tsou, Amy Shiuan, Cynthia L. Wladyka, Dmytro Rudoy, Jin Yeong Kim, Jennifer A. Waters, Samantha L. Schuster, Ilsa M. Coleman, Mridu Kapur, Marek Sobczyk, Christopher D. Katanski, Amin M. Bayat Tork, Wen Zhang, Peter S. Nelson, Gavin Ha, Michael C. Haffner, Eva Corey, Colm Morrissey, Yuzhuo Wang, Arvind R. Subramaniam, John K. Lee, Susan L. Ackerman, Tao Pan, Andrew C. Hsieh
Read the Full Article.
You can also read: 10 Prostate Cancer Trials to Watch at ESMO 2026
